09/01/2026 | Press release | Distributed by Public on 09/01/2026 08:42
Lake Street Capital Markets Analyst, Frank Takkinen, initiated coverage of Beyond Air, Inc. with a BUY rating and price target of $10 (XAIR-$10). Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments.